<DOC>
	<DOCNO>NCT00314366</DOCNO>
	<brief_summary>Recent study suggest may possible grow new blood vessel ( angiogenesis ) supply heart muscle currently get enough blood . One theory certain type stem cell , aldehyde dehydrogenase bright stem cell , may stimulate growth new vessel . After bone marrow procedure , special cell separate inject back heart around area damage special guidance injection system . Once patient meet inclusion criterion exclusion criterion , he/she consent study extensive baseline testing complete St. Luke 's Episcopal Hospital Houston , Texas . Once baseline criterion meet , patient his/her bone marrow harvest later inject , randomize receive active treatment . The day bone marrow harvest , patient take cardiac catheterization lab NOGA mapping perform processed cell placebo inject electromechanical guidance affect area leave ventricle . The patient usually discharge home next day return follow-up week 1 4 , month 3 6 , one year unless crossover he/she begin baseline 6 month follow-up one year . Follow-up testing , include quality life NOGA mapping , do time injection , well 6 month .</brief_summary>
	<brief_title>Intramyocardial Injection Autologous Aldehyde Dehydrogenase-Bright Stem Cells Therapeutic Angiogenesis ( FOCUS Br )</brief_title>
	<detailed_description>This phase I , double blind trial evaluate use Aldehyde Dehydrogenase-Bright ( ALDHbr ) ischemic cardiomyopathy patient . The study hypothesis transendocardial injection autologous bone marrow cell patient end-stage ischemic heart disease safe , provide neovascularization , improve perfusion myocardial contractility . The primary object study ass safety ALDHbr cell injection . The efficacy base upon treadmill MVO2 . A maximum 60 patient enrol study . At end 6 month , require testing complete , patient tell whether control group . The patient control group give option crossover actually receive stem cell injection . At time crossover , become baseline , patient begin follow-up test include clinic visit one year total 18 month follow-up .</detailed_description>
	<mesh_term>Coronary Artery Disease</mesh_term>
	<mesh_term>Myocardial Ischemia</mesh_term>
	<mesh_term>Coronary Disease</mesh_term>
	<criteria>Canadian cardiovascular ( CV ) Class IIIV angina and/or congestive heart failure ( CHF ) symptoms Ejection fraction less equal 45 % Reversible perfusion defect single photon emission compute tomography ( SPECT ) Coronary artery disease ( CAD ) unable correct surgery ( bypass ) intervention ( stent ) Able walk treadmill Hemodynamically stable Age le 18 great 70 Atrial fibrillation Severe valve disease History cancer last 5 year HIV positive ; hepatitis B C positive . Left ventricular wall thickness le 8 mm Recent heart attack within last 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>stem cell</keyword>
	<keyword>autologous</keyword>
	<keyword>ischemia</keyword>
</DOC>